Clinical Trials

Tempus AI stock rises 3.5% after unveiling HRD-RNA algorithm for cancer detection

Tempus AI shares climbed Wednesday following the launch of its new HRD-RNA algorithm, an AI-driven tool designed to detect homologous recombination deficiency in tumors. The algorithm analyzes gene expression to identify patients who may benefit from platinum-based chemotherapy or PARP inhibitors, offering a more dynamic assessment than traditional genomic methods.